The pathogenesis of prion diseases is related to conformational transformation of cellular prion protein (PrP C ) into a toxic, infectious, and self-replicating conformer termed PrP Sc . Following extracerebral inoculation, the replication of PrP Sc is confined for months to years to the lymporeticular system (LRS) before the secondary CNS involvement results in occurrence of neurological symptoms. Therefore, replication of PrP Sc , in the early stage of infection can be targeted by therapeutic approaches, which like passive immunization have limited blood-brain-barrier penetration. In this study, we show that 6D11 anti-PrP monoclonal antibody (Mab) prevents infection on a FDC-P1 myeloid precursor cell line stably infected with 22L mouse adapted scrapie strain. Passive immunization of extracerebrally infected CD-1 mice with Mab 6D11 resulted in effective suppression of PrP Sc replication in the LRS. Although, a rebound of PrP Sc presence occurred when the Mab 6D11 treatment was stopped, passively immunized mice showed a prolongation of the incubation period by 36.9% (p b 0.0001) and a significant decrease in CNS pathology compared to control groups receiving vehicle or murine IgG. Our results indicate that antibody-based therapeutic strategies can be used, even on a short-term basis, to delay or prevent disease in subjects accidentally exposed to prions.
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Introduction
Prion diseases (prionoses) are transmissible, invariably fatal, neurodegenerative diseases associated with a conformational transformation of cellular prion protein PrP C into a toxic, infectious, and selfreplicating PrP Sc conformer for which no effective treatment is currently available (Prusiner, 2001; Sadowski et al., 2008; Weissmann, 2004 (Eklund et al., 1967; Hilton et al., 2004b; Mabbott and MacPherson, 2006; Rubenstein et al., 1991) . During this period, asymptomatic vCJD carriers constitute a reservoir of infection. It is estimated that more than 10,000 Britons could be vCJD infected as a result of BSE exposure during the early 90s epidemics, yet remain asymptomatic carriers of prionoses (Hilton et al., 2004a; Hilton, 2006) . The four possible cases of disease transmission related to blood transfusion donated by asymptomatic individuals infected with vCJD, published so far, justify clinical concerns of more wide spread blood bank contamination (Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 2006) . In addition to transmission via blood transfusion and organ transplantation, human to human transmission may also occur via infectious material transferred by surgical (especially neurosurgical) (Weissmann et al., 2002) or dental tools (Porter, 2003) and endoscopic instruments since PrP Sc is known to accumulate in the intestinal mucosa of asymptomatic BSE-infected carriers (Prinz et al., 2003; Wadsworth et al., 2001 ). 
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